The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody.

about

The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody.

Item

http://www.wikidata.org/entity/Q55211396

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The Potential Close Future of ...... I with an Engineered Antibody.

@en

The Potential Close Future of ...... I with an Engineered Antibody.

@nl

type

Item

label

The Potential Close Future of ...... I with an Engineered Antibody.

@en

The Potential Close Future of ...... I with an Engineered Antibody.

@nl

prefLabel

The Potential Close Future of ...... I with an Engineered Antibody.

@en

The Potential Close Future of ...... I with an Engineered Antibody.

@nl

P1476

The Potential Close Future of ...... I with an Engineered Antibody.

@en

P2093

Wolfgang Korte

http://www.w3.org/2001/XMLSchema#string

P2860

New insights into the biology of tissue factor pathway inhibitor

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity

Tissue factor pathway inhibitor (TFPI)--an update.

Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation.

Modulation of mouse coagulation gene transcription following acute in vivo delivery of synthetic small interfering RNAs targeting HNF4α and C/EBPα.

A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.

Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.

Targeting TFPI for hemophilia treatment.

P304

92-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000488152

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

L Graf

P577

2018-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29765291

http://www.w3.org/2001/XMLSchema#string

P932

5939805

http://www.w3.org/2001/XMLSchema#string